Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
10.1002/cncr.26372
Saved in:
Main Authors: | De Lima Lopes Jr., G., Segel, J.E., Tan, D.S.W., Do, Y.K., Mok, T., Finkelstein, E.A. |
---|---|
Other Authors: | DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE |
Format: | Article |
Published: |
2016
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/124662 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
by: Ku, G.Y., et al.
Published: (2016) -
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014) -
Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
by: Verma, Akash, et al.
Published: (2017) -
Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
by: Soon, Jonathan Jian Hao, et al.
Published: (2023) -
Rare subtypes of adenocarcinoma of the lung
by: Ou, S.-H.I., et al.
Published: (2014)